netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
06.01.02.03  Expand sub section  Other antidiabetic drugs
06.01.02.03  Expand sub section  Alpha glucosidase inhibitors
06.01.02.03  Expand sub section  DPP4 inhibitors (gliptins)
Sitagliptin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
AAAAAAAA

Sitagliptin is the only DPP-4i 'gliptin' on the NCL Formulary. See NCL guidance

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Restricted to initiation by endocrinology only
    • See link below
  • RNOH:
    • Restricted Requires initiation by a Diabetes Specialist
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NCL JFC: Antihyperglycaemic agents for Type 2 diabetes
Saxagliptin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
AAAAAAAA

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to initiation by endocrinology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
06.01.02.03  Expand sub section  GLP1 agonists
06.01.02.03  Expand sub section  Meglitinides to top
06.01.02.03  Expand sub section  SGL2 inhibitors
06.01.02.03  Expand sub section  Thiazolidinediones
 ....
 Non Formulary Items
Alogliptin

View adult BNF View SPC online View childrens BNF
Non Formulary
Linagliptin

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not approved for Type 2 diabetes, with or without renal impairment (June 2016)

Vildagliptin

View adult BNF View SPC online View childrens BNF
Non Formulary
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Homecare
Homecare

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.  

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary